United Therapeutics dedicated its new $32 million, 50,000-square-foot, four-story research and production facility in Silver Spring on June 26, 2006. The building is the first phase of the drugmaker’s expansion project. Phase II of their headquarters building is under construction.
United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular and infectious diseases. In these segments, United Therapeutics is actively developing three technology platforms: Prostacyclin Analogs, Glycobiology, and Telemedicine.
At United Therapeutics, we find tremendous inspiration for our work and view our products as being new beginnings for patients and doctors, with quality of life as our utmost therapeutic goal. The theme of United Therapeutics is "Medicines for Life" because all of our therapeutics address life-threatening illnesses.
Much of United Therapeutics' resources are focused on cardiovascular health, including developing analogs of the endogenous hormone prostacyclin for the treatment of pulmonary arterial hypertension and critical limb ischemia and a variety of telemedicine services for patients with an array of possible cardiac arrhythmias. United Therapeutics's second focus is in the field of infectious disease, where the company is targeting hepatitis C and other diseases with unique glycobiology compounds. While this work is at an early stage, it holds immense promise. The diseases being targeted afflict over a billion people worldwide, and the compounds are part of an entire new class of pharmacological agents.